ATE322269T1 - Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung - Google Patents

Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung

Info

Publication number
ATE322269T1
ATE322269T1 AT02782507T AT02782507T ATE322269T1 AT E322269 T1 ATE322269 T1 AT E322269T1 AT 02782507 T AT02782507 T AT 02782507T AT 02782507 T AT02782507 T AT 02782507T AT E322269 T1 ATE322269 T1 AT E322269T1
Authority
AT
Austria
Prior art keywords
aripiprazole
production
active substance
low hygroscopy
hygroscopy
Prior art date
Application number
AT02782507T
Other languages
English (en)
Inventor
Takuji Bando
Satoshi Aoki
Junichi Kawasaki
Makoto Ishigami
Youichi Taniguchi
Tsuyoshi Yabuuchi
Kiyoshi Fujimoto
Noriyuki Kobayashi
Tsutomu Fujimura
Masanori Takahashi
Kaoru Abe
Koichi Shinhama
Naoto Utsumi
Michiaki Tominaga
Yoshihiro Oi
Shohei Yamada
Kenji Tomikawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27171631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE322269(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA 2379005 external-priority patent/CA2379005A1/en
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of ATE322269T1 publication Critical patent/ATE322269T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
AT02782507T 2001-09-25 2002-09-25 Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung ATE322269T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001290645 2001-09-25
JP2001348276 2001-11-14
CA 2379005 CA2379005A1 (en) 2001-09-25 2002-03-27 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof

Publications (1)

Publication Number Publication Date
ATE322269T1 true ATE322269T1 (de) 2006-04-15

Family

ID=27171631

Family Applications (5)

Application Number Title Priority Date Filing Date
AT04002427T ATE464050T1 (de) 2001-09-25 2002-09-25 Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung
AT02782507T ATE322269T1 (de) 2001-09-25 2002-09-25 Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung
AT08000359T ATE465737T1 (de) 2001-09-25 2002-09-25 Gering hygroskopische aripiprazol-substanz (kristal d) und herstellungsverfahren
AT08000360T ATE467416T1 (de) 2001-09-25 2002-09-25 Gering hygroskopische aripiprazol-substanz (kristal e) und herstellungsverfahren
AT08000357T ATE465736T1 (de) 2001-09-25 2002-09-25 Gering hygroskopische aripiprazol-substanz (kristal f) und herstellungsverfahren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04002427T ATE464050T1 (de) 2001-09-25 2002-09-25 Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung

Family Applications After (3)

Application Number Title Priority Date Filing Date
AT08000359T ATE465737T1 (de) 2001-09-25 2002-09-25 Gering hygroskopische aripiprazol-substanz (kristal d) und herstellungsverfahren
AT08000360T ATE467416T1 (de) 2001-09-25 2002-09-25 Gering hygroskopische aripiprazol-substanz (kristal e) und herstellungsverfahren
AT08000357T ATE465736T1 (de) 2001-09-25 2002-09-25 Gering hygroskopische aripiprazol-substanz (kristal f) und herstellungsverfahren

Country Status (23)

Country Link
US (20) US20040058935A1 (de)
EP (6) EP1419776B2 (de)
JP (3) JP3760264B2 (de)
CN (16) CN101792415A (de)
AR (2) AR033485A1 (de)
AT (5) ATE464050T1 (de)
AU (1) AU2002334413C1 (de)
BR (1) BR0205391A (de)
CA (6) CA2688915C (de)
CY (1) CY1118195T1 (de)
DE (5) DE60236383D1 (de)
DK (5) DK1927355T3 (de)
ES (5) ES2343220T3 (de)
HU (1) HUP0600141A3 (de)
IL (3) IL153838A0 (de)
MX (1) MXPA03000440A (de)
NO (7) NO328134B1 (de)
PE (1) PE20090124A1 (de)
PL (1) PL225415B1 (de)
PT (5) PT1419776E (de)
SI (4) SI1330249T1 (de)
UA (1) UA84764C2 (de)
WO (1) WO2003026659A1 (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
UA79984C2 (en) * 2002-08-20 2007-08-10 Bristol Myers Squibb Co Preparation on the basis of aripiprazole complex and use thereof
WO2004043358A2 (en) * 2002-11-08 2004-05-27 Bristol-Myers Squibb Company Formulations of low solubility bioactive agents and processes for making the same
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
RU2356554C2 (ru) 2002-12-27 2009-05-27 Оцука Фармасьютикал Ко., Лтд. Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств
DK1480953T4 (da) † 2003-01-09 2010-11-15 Otsuka Pharma Co Ltd Fremgangsmåde til fremstilling af aripiprazol
EP1618103A2 (de) * 2003-04-25 2006-01-25 Cadila Healthcare Ltd. Polymorphe von aripiprazol
DK1626721T3 (en) 2003-05-23 2017-01-23 Otsuka Pharma Co Ltd CARBOSTYRIL DERIVATIVES AND Mood Stabilizers for the Treatment of Mood Disorders
WO2005009990A1 (en) * 2003-07-25 2005-02-03 Hetero Drugs Limited Aripiprazole crystalline forms
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
AU2004285448C1 (en) 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
ATE529409T1 (de) 2003-12-16 2011-11-15 Teva Pharma Verfahren zur herstellung von kristallinen aripiprazolformen
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
US20050215791A1 (en) * 2004-02-05 2005-09-29 Ben-Zion Dolitzky Process for preparing aripiprazole
CA2559824A1 (en) 2004-02-05 2006-01-05 Teva Pharmaceutical Industries Ltd. Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
EP1797039A1 (de) * 2004-09-13 2007-06-20 Matrix Laboratories Ltd Verfahren zur herstellung von polymorphen, solvaten von aripiprazol unter verwendung von aripiprazolsäuresalzen
JP4819818B2 (ja) 2004-10-08 2011-11-24 スベン ライフ サイエンシズ リミティド アリピプラゾールの製造方法、並びに対応する中間体及びそれらの製造
CN100338038C (zh) * 2004-10-14 2007-09-19 重庆医药工业研究院有限责任公司 阿立派唑的新晶型及其制备方法
WO2006053780A1 (en) 2004-11-18 2006-05-26 Synthon B.V. Crystalline aripiprazole solvates
CN101111481A (zh) * 2004-11-18 2008-01-23 斯索恩有限公司 制备结晶阿立哌唑的方法
SI1844036T1 (sl) 2005-01-27 2015-12-31 Sandoz Ag Postopek za pripravo aripiprazola
EP1686117A1 (de) * 2005-01-27 2006-08-02 Sandoz AG Polymorph und Solvate von Aripiprazol
CA2600542A1 (en) 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
AU2006224759A1 (en) † 2005-03-17 2006-09-21 Synthon B.V. Process of making crystalline Type II aripiprazole
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
CA2605128A1 (en) * 2005-04-15 2007-01-11 Medichem, S.A. Syntheses and preparations of polymorphs of crystalline aripiprazole
CN100432053C (zh) * 2005-06-07 2008-11-12 上海医药工业研究院 阿立哌唑晶型及其制备方法
HUP0500683A3 (en) * 2005-07-14 2009-03-30 Egis Gyogyszergyar Nyilvanosan New arylpiprazole salts for producing pharmaceutical composition
EP1793801A1 (de) * 2005-07-15 2007-06-13 Teva Pharmaceutical Industries Ltd. Neues granulationsverfahren und damit hergestelltes granulat
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
US20070014864A1 (en) * 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
EP1933814A2 (de) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoteilchenförmige aripiprazol-formulierungen
BRPI0606163A2 (pt) 2005-09-29 2009-05-26 Teva Pharma métodos para preparar aripiprazola anidra forma ii
CZ299485B6 (cs) * 2005-10-11 2008-08-13 Zentiva, A. S. Zpusob výroby aripiprazolu
EP1919453A2 (de) * 2005-12-22 2008-05-14 Teva Pharmaceutical Industries Ltd Verfahren zur reduktion der teilchengrösse von aripiprazol
PT1808165E (pt) * 2006-01-05 2009-06-09 Teva Pharma Formulações secas de aripiprazole
DE602006004694D1 (de) * 2006-01-05 2009-02-26 Teva Pharma Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
TWI394753B (zh) 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
EP1880714A1 (de) 2006-07-20 2008-01-23 Helm AG Amorphes Aripiprazol und Verfahren zu dessen Herstellung
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
TR200604349A2 (tr) 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
EP2084133A2 (de) * 2006-09-28 2009-08-05 Cadila Healthcare Limited Verfahren zur herstellung von kristallinem aripiprazol
WO2008051541A2 (en) * 2006-10-24 2008-05-02 Cambrex Charles City, Inc. Process for preparing anhydrous aripirazole type i
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
WO2009001697A2 (en) * 2007-06-25 2008-12-31 Otsuka Pharmaceutical Co., Ltd. Microspheres having core/shell structure
JP4879349B2 (ja) * 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
PT2082735E (pt) * 2008-01-23 2010-10-12 Helm Ag Aripripazole amorfo e processo para a sua preparação
WO2010079506A2 (en) 2008-06-23 2010-07-15 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of aripiprazole
EP2233471A1 (de) 2009-02-06 2010-09-29 Adamed Sp. z o.o. Salz aus 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4.dihydro-2(1h)-chinolinon mit 5-sulfosalizyklischer säure und herstellungsverfahren
WO2010106551A2 (en) * 2009-03-09 2010-09-23 Neuland Laboratories Ltd. A process for the manufacture of pure anhydrous aripiprazole form b
EP2238976B1 (de) 2009-04-03 2012-06-27 Hexal AG Oraler Film mit 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-chinolin-2-on-Base oder Salze oder Hydrate davon
US20120214820A1 (en) 2009-09-15 2012-08-23 Ratiopharm Gmbh Orally disintegrating pharmaceutical dosage form containing aripiprazole
CN102372672B (zh) * 2010-08-24 2014-06-04 重庆圣华曦药业股份有限公司 低吸湿性阿立哌唑晶体iv、制备方法及其应用
CN101948426A (zh) * 2010-09-13 2011-01-19 浙江华海药业股份有限公司 一种制备阿立哌唑晶型b的新方法
JP2012121850A (ja) * 2010-12-09 2012-06-28 Otsuka Pharmaceut Co Ltd アリピプラゾールの経口速溶性組成物
CN102060763B (zh) * 2010-12-27 2012-11-14 齐鲁制药有限公司 微粉型阿立哌唑晶型ⅰ或ⅱ的制备方法
FI3156056T3 (fi) 2011-03-18 2024-03-01 Alkermes Pharma Ireland Ltd Sorbitaaniestereitä käsittäviä farmaseuttisia koostumuksia
WO2012131451A1 (en) 2011-03-30 2012-10-04 Jubilant Life Sciences Limited Process for producing aripiprazole in anhydrous type i crystals
KR101340214B1 (ko) 2011-03-31 2013-12-10 주식회사 대웅제약 무수 아리피프라졸 ⅱ형 결정의 제조방법
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
JP6034377B2 (ja) * 2011-06-27 2016-11-30 シャンハイ チョンシ ファーマシューティカル コーポレイション アリピプラゾール医薬製剤及びその調製方法
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
TW201309651A (zh) * 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
CN103172563B (zh) * 2011-12-26 2015-03-25 北京京卫燕康药物研究所有限公司 小粒径的晶型i阿立哌唑的工业化制备
CN102584858B (zh) * 2011-12-31 2014-11-12 广州医药工业研究院 乳酸左旋尤利沙星晶体及其制备方法和用途
AR090245A1 (es) 2012-03-06 2014-10-29 Otsuka Pharma Co Ltd Preparacion solida oral de liberacion sostenida, metodo de preparacion
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
ES2950418T3 (es) 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
US20150174247A1 (en) 2012-06-29 2015-06-25 Maruishi Pharmaceutical Co., Ltd. Oral pharmaceutical preparation of aripiprazole
KR101372840B1 (ko) * 2012-08-02 2014-03-12 주식회사 에스텍파마 무수 아리피프라졸 결정의 제조방법
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
JP2014114243A (ja) * 2012-12-11 2014-06-26 Ohara Yakuhin Kogyo Kk 安定な固形製剤の製造方法
CN104072416B (zh) * 2013-03-26 2017-06-20 江苏恩华药业股份有限公司 一种制备阿立哌唑结晶b的方法
AR096131A1 (es) * 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
WO2014178334A1 (en) * 2013-04-30 2014-11-06 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150093441A1 (en) * 2013-09-30 2015-04-02 Otsuka Pharmaceutical Co., Ltd Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
EP3065700A1 (de) 2013-11-07 2016-09-14 Synthon B.V. Im mund zerfallende pharmazeutische zusammensetzungen mit aripiprazol
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
KR102426097B1 (ko) * 2014-08-18 2022-07-28 삼성전자주식회사 전자 장치의 안테나
MA55917A (fr) * 2014-08-25 2022-03-16 Alkermes Pharma Ireland Ltd Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
JP6023770B2 (ja) * 2014-10-01 2016-11-09 株式会社パーマケム・アジア アリピプラゾール無水物ｂ形結晶の製造方法
EP3233077A4 (de) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamin-d2-rezeptor-liganden
WO2016138536A2 (en) * 2015-02-27 2016-09-01 Tactual Labs Co. Alterable ground plane for touch surfaces
WO2016181406A1 (en) * 2015-05-08 2016-11-17 Davuluri Ramamohan Rao Improved process for the preparation of aripiprazole with reduced particle size
JP6071083B2 (ja) * 2015-06-12 2017-02-01 大原薬品工業株式会社 安定性が改善された、アリピプラゾールを含有する散剤
JP2015172084A (ja) * 2015-07-06 2015-10-01 大塚製薬株式会社 アリピプラゾールの経口速溶性組成物
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
US10913721B2 (en) 2016-02-19 2021-02-09 Nanjing Noratech Pharmaceuticals Co., Ltd Crystalline form of aripiprazole
TWI665194B (zh) * 2016-02-19 2019-07-11 諾瑞特國際藥業股份有限公司 阿立哌唑的新晶型
US20190070174A1 (en) * 2016-03-10 2019-03-07 The Regents Of The University Of Michigan Methods of treating neurodegenerative diseases
ES2922379T3 (es) 2016-12-16 2022-09-14 Janssen Pharmaceutica Nv Compuestos de imidazo[4,5,D]pirrolo[2,3,B]piridina como inhibidores de Janus quinasas
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
JP6572257B2 (ja) * 2017-05-16 2019-09-04 大塚製薬株式会社 アリピプラゾールの経口速溶性組成物
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
EP3870292A4 (de) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Kombination von serotonin-spezifischem wiederaufnahmeinhibitor und serotonin-1a-rezeptor-partialagonist zur verminderung von l-dopa-induzierter dyskinesie
JP7211136B2 (ja) * 2019-02-14 2023-01-24 ニプロ株式会社 錠剤、および、その製造方法
CN110128337A (zh) * 2019-06-10 2019-08-16 岳阳新华达制药有限公司 一种阿立哌唑晶型b的制备方法
KR102128883B1 (ko) 2019-10-02 2020-07-01 (주)삼화바이오팜 고순도 아리피프라졸의 신규 결정형 및 이의 제조방법
CA3212191A1 (en) 2020-04-01 2021-10-07 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
EP4043008A1 (de) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit aripiprazol
JP2024509587A (ja) 2021-03-11 2024-03-04 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋ媒介性障害の治療に使用するためのｌｏｒｐｕｃｉｔｉｎｉｂ
CN120957722A (zh) 2023-04-26 2025-11-14 大塚制药株式会社 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动
CN117309825B (zh) * 2023-11-30 2024-04-09 四川蜀道建筑科技有限公司 一种透光检测亚甲蓝mb值的设备
CN118878462B (zh) * 2024-06-12 2025-05-09 青岛科技大学 一种药物微晶水中制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS62149664A (ja) 1978-03-30 1987-07-03 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体の製造法
JPS5646812A (en) 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS55127371A (en) 1980-02-14 1980-10-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4438119A (en) 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
DK588486A (da) 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4771053A (en) 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US5162375A (en) * 1988-05-06 1992-11-10 Beecham Group P.L.C. Treatment of neuronal degeneration with 5HT1A agonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
DK391189A (da) * 1988-08-10 1990-02-11 Otsuka Pharma Co Ltd Carbostyrilderivater
US5200410A (en) * 1988-09-20 1993-04-06 Troponwerke Gmbh & Co. Medicaments for the treatment of cerebral apoplexy
DE3831888A1 (de) 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg Arzneimittel zur behandlung von apoplexia cerebri
FR2637591B1 (fr) * 1988-10-11 1992-10-23 Synthelabo Derives de quinoleinone, leur preparation et leur application en therapeutique
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5073377A (en) * 1988-11-03 1991-12-17 Miles Inc. Method of preparing oral dosage forms with a granulating composition
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
WO1992010200A1 (en) 1990-12-14 1992-06-25 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
CA2067475C (en) * 1991-05-08 2000-10-10 Yasuo Oshiro Carbostyril derivatives and their use
EP0586525B1 (de) 1991-05-20 1997-04-16 PHARMACIA & UPJOHN COMPANY Karboxamido-(1,2n)-karbocyclo-2-aminotetralinderivate
DE4135551A1 (de) 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
US5292766A (en) 1992-03-25 1994-03-08 Eli Lilly And Company Method for improving primary memory and/or learning
AU5446894A (en) 1992-10-23 1994-05-24 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2506547B2 (ja) 1993-06-16 1996-06-12 ミナミ産業株式会社 豆腐のパック詰め装置
JP2959615B2 (ja) 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH07247271A (ja) * 1994-01-21 1995-09-26 Otsuka Pharmaceut Co Ltd ３，４−ジヒドロカルボスチリル誘導体
US5663178A (en) * 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
US5504093A (en) * 1994-08-01 1996-04-02 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication
JP2987484B2 (ja) 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
JPH0940648A (ja) 1995-08-02 1997-02-10 Yamanouchi Pharmaceut Co Ltd 新規な８−（２−アミノアルコキシ）キノリン誘導体
US5766748A (en) 1995-11-30 1998-06-16 Mitsui Chemicals, Inc. Stretched film of lactic acid-based polymer
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
NZ508303A (en) 1996-05-07 2001-07-27 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone) useful as a dopamine D2 antagonist
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
EP1014977A1 (de) 1996-08-22 2000-07-05 Glaxo Group Limited Diagnose von migraine begleitet von aura, depression und angst durch allelvariationen in dopaminergen genen
CA2264080A1 (en) 1996-08-27 1998-03-05 Richard Eric Mewshaw 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
AU2575399A (en) 1998-02-03 1999-08-16 American Home Products Corporation Oxazole derivatives as serotonin-1a receptor agonists
JP2001089128A (ja) * 1998-04-10 2001-04-03 Asahi Glass Co Ltd 球状シリカ粒子の製造方法
AU3555099A (en) 1998-04-13 1999-11-01 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
EP1076647A2 (de) * 1998-04-29 2001-02-21 American Home Products Corporation Antipsychotisch wirkende indolyl-derivate
JPH11335286A (ja) 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
US20030027817A1 (en) * 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
MXPA02007095A (es) 2000-01-19 2003-04-14 Akzo Nobel Nv Combinacion de farmacos para el tratamiento de la depresion y desordenes relacionados que comprenden mirtazapina.
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
JP4197088B2 (ja) 2000-06-05 2008-12-17 電気化学工業株式会社 低密度かつ低ガス透過性六方晶窒化硼素焼結体及びその製造方法
EP1353675A2 (de) 2001-01-02 2003-10-22 PHARMACIA & UPJOHN COMPANY Neue kombination von norepinehrin reuptake hemmern und neuroleptika
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
DK1397145T3 (da) 2001-06-19 2007-01-02 Norbert Mueller Anvendelse af COX-2-inhibitorer til behandling af schizophrenia eller tics-lidelser
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2003238393A (ja) 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
DK1626721T3 (en) 2003-05-23 2017-01-23 Otsuka Pharma Co Ltd CARBOSTYRIL DERIVATIVES AND Mood Stabilizers for the Treatment of Mood Disorders
AU2004285448C1 (en) 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
AU2007271749A1 (en) * 2006-07-12 2008-01-17 Nerviano Medical Sciences S.R.L. Crystalline nemorubicin hydrochloride
JPWO2009072334A1 (ja) 2007-12-03 2011-04-21 富田製薬株式会社 製剤用核粒子
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament

Also Published As

Publication number Publication date
ATE465736T1 (de) 2010-05-15
EP1927357B1 (de) 2010-05-12
EP1330249A1 (de) 2003-07-30
US20160251315A1 (en) 2016-09-01
US20070203151A1 (en) 2007-08-30
AU2002334413C9 (en) 2015-04-09
CA2689051C (en) 2011-03-08
NO20081631L (no) 2003-01-17
DE60236229D1 (de) 2010-06-10
PL360900A1 (en) 2004-09-20
US20070202181A1 (en) 2007-08-30
US20190225584A1 (en) 2019-07-25
US20070213343A1 (en) 2007-09-13
CY1118195T1 (el) 2017-06-28
NO336679B1 (no) 2015-10-19
DK1419776T3 (da) 2010-07-05
US20070203152A1 (en) 2007-08-30
JP2006070045A (ja) 2006-03-16
CN1699346A (zh) 2005-11-23
EP1927356B1 (de) 2010-04-28
DE60236383D1 (de) 2010-06-24
ES2343220T3 (es) 2010-07-26
EP1419776A2 (de) 2004-05-19
PT1927355E (pt) 2010-06-11
DE60210409T2 (de) 2006-11-16
CN101792415A (zh) 2010-08-04
CN106420640A (zh) 2017-02-22
NO328134B1 (no) 2009-12-14
IL153838A (en) 2008-04-13
US20140309236A1 (en) 2014-10-16
EP1925308B1 (de) 2016-08-31
JP2004256555A (ja) 2004-09-16
EP1419776B2 (de) 2017-07-19
EP1927356A1 (de) 2008-06-04
IL188455A0 (en) 2008-03-20
WO2003026659A1 (en) 2003-04-03
CN1817882B (zh) 2011-09-07
EP1419776A3 (de) 2004-06-16
CN101434575A (zh) 2009-05-20
SI1927356T1 (sl) 2010-07-30
US20070213344A1 (en) 2007-09-13
CN106420627A (zh) 2017-02-22
CN106692151A (zh) 2017-05-24
US8901130B2 (en) 2014-12-02
ES2343179T3 (es) 2010-07-26
EP1330249B1 (de) 2006-04-05
NO336262B1 (no) 2015-07-06
DE60235995D1 (de) 2010-05-27
SI1419776T2 (sl) 2017-12-29
CA2689051A1 (en) 2003-04-03
US8399469B2 (en) 2013-03-19
CA2688860A1 (en) 2003-04-03
CN101434574A (zh) 2009-05-20
SI1927355T1 (sl) 2010-07-30
ES2261750T3 (es) 2006-11-16
NO20081626L (no) 2003-01-17
EP1419776A9 (de) 2004-09-08
JP3760264B2 (ja) 2006-03-29
CA2688934A1 (en) 2003-04-03
PT1419776E (pt) 2010-04-28
CN101579343B (zh) 2012-04-18
EP1419776A8 (de) 2004-09-01
CN101579343A (zh) 2009-11-18
NO20030247D0 (no) 2003-01-17
EP1419776B1 (de) 2010-04-14
US20070203150A1 (en) 2007-08-30
CN101574347B (zh) 2012-02-29
US20120315302A1 (en) 2012-12-13
CN101579344A (zh) 2009-11-18
DK1330249T3 (da) 2006-08-07
CN101423493A (zh) 2009-05-06
SI1330249T1 (sl) 2006-10-31
CA2426921A1 (en) 2003-04-03
SI1419776T1 (sl) 2010-07-30
US20150225347A1 (en) 2015-08-13
US20120000998A1 (en) 2012-01-05
US20040058935A1 (en) 2004-03-25
US20140030523A1 (en) 2014-01-30
DE60236231D1 (de) 2010-06-10
CN101579344B (zh) 2012-05-30
US20120316180A1 (en) 2012-12-13
CN101574348B (zh) 2012-02-22
CN101434573B (zh) 2011-12-07
ES2343179T5 (es) 2017-10-19
NO336264B1 (no) 2015-07-06
DK1419776T4 (en) 2017-09-04
CN1817882A (zh) 2006-08-16
US20070212421A1 (en) 2007-09-13
CA2689052C (en) 2011-02-15
US8993761B2 (en) 2015-03-31
PT1927357E (pt) 2010-06-08
BR0205391A (pt) 2003-07-29
NO336263B1 (no) 2015-07-06
EP1927355B1 (de) 2010-04-28
CA2688934C (en) 2011-05-17
US20200123110A1 (en) 2020-04-23
MXPA03000440A (es) 2003-10-06
PL225415B1 (pl) 2017-04-28
PT1330249E (pt) 2006-06-30
US8017615B2 (en) 2011-09-13
US20120016123A1 (en) 2012-01-19
US20120316179A1 (en) 2012-12-13
NO20091689L (no) 2003-01-17
NO20030247L (no) 2003-01-17
US20210395204A1 (en) 2021-12-23
EP1927357A2 (de) 2008-06-04
US8580796B2 (en) 2013-11-12
AU2002334413B2 (en) 2004-11-04
CA2688915A1 (en) 2003-04-03
AR033485A1 (es) 2003-12-26
DK1927356T3 (da) 2010-07-26
NO20081633L (no) 2003-01-17
US10150735B2 (en) 2018-12-11
EP1927355A1 (de) 2008-06-04
HUP0600141A3 (en) 2008-03-28
US8703773B2 (en) 2014-04-22
JP4614870B2 (ja) 2011-01-19
DK1927357T3 (da) 2010-08-16
CA2688915C (en) 2011-02-01
ES2343602T3 (es) 2010-08-04
EP1925308A1 (de) 2008-05-28
NO336265B1 (no) 2015-07-06
PE20090124A1 (es) 2009-03-07
EP1927357A3 (de) 2008-06-11
NO20081632L (no) 2003-01-17
CN101434573A (zh) 2009-05-20
ATE467416T1 (de) 2010-05-15
CN101574348A (zh) 2009-11-11
CN101423492B (zh) 2013-08-28
PT1927356E (pt) 2010-05-24
US7910589B2 (en) 2011-03-22
US8901303B2 (en) 2014-12-02
IL153838A0 (en) 2003-07-31
CN101574347A (zh) 2009-11-11
US9359302B2 (en) 2016-06-07
AU2002334413C1 (en) 2021-08-12
CN1463191A (zh) 2003-12-24
NO20081627L (no) 2003-01-17
UA84764C2 (en) 2008-11-25
DK1927355T3 (da) 2010-07-19
CA2426921C (en) 2011-03-15
JP3750023B2 (ja) 2006-03-01
CN101423492A (zh) 2009-05-06
ES2343219T3 (es) 2010-07-26
JP2003212852A (ja) 2003-07-30
DE60210409D1 (de) 2006-05-18
AR056503A2 (es) 2007-10-10
HUP0600141A2 (hu) 2006-05-29
ATE465737T1 (de) 2010-05-15
US8642760B2 (en) 2014-02-04
CN101434574B (zh) 2011-12-14
ATE464050T1 (de) 2010-04-15
CA2689052A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
ATE464050T1 (de) Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung
DE60233058D1 (de) Silsesquioxanderivate und verfahren zu ihrer herstellung
DE60231548D1 (de) N; formkörper und verfahren zu ihrer herstellung
DE50214717D1 (de) Und verfahren zu seiner herstellung
AT501583B8 (de) Dualband-antenne und verfahren zu ihrer herstellung
DE60201475D1 (de) Mit Polyhydroxyalkanoat beschichtetes Liposom und Verfahren zu seiner Herstellung
DE50101931D1 (de) Substituierte sulfonylaminomethylbenzoesäure(derivate) und verfahren zu ihrer herstellung
DE60031949D1 (de) Leiterplatte und verfahren zu ihrer herstellung
DE60042914D1 (de) Halbleitervorrichtung und verfahren zu ihrer herstellung
DE60115902D1 (de) Osteoimplantat und verfahren zu seiner herstellung
DE60221201D1 (de) Polyoxyalkylen-derivate und Verfahren zu ihrer Herstellung
DE60134540D1 (de) Töchiometrie aufweisender isolierschicht und verfahren zur herstellung
DE60111195D1 (de) Wässerige formulierungen und verfahren zu ihrer herstellung
DE60230486D1 (de) Display-vorrichtung und verfahren zu ihrer herstellung
DE60112131D1 (de) Haftfreudige klebefolie und verfahren zu ihrer herstellung
DE60124428D1 (de) Lüftungsvorrichtung und verfahren zu dessen herstellung
DE60116486D1 (de) Gallengangstent und verfahren zu seiner herstellung
DE60111904D1 (de) Biosensor und verfahren zu dessen herstellung
DE60318167D1 (de) Arzneiform und Verfahren zu ihrer Herstellung
DE60226677D1 (de) Saw-einrichtung und verfahren zu ihrer herstellung
DE60226707D1 (de) Kunsthaare und verfahren zu deren herstellung
DE60144157D1 (de) Elektrochemische einrichtung und verfahren zu ihrer herstellung
DE60218734D1 (de) Dehnbare verbundfolie und verfahren zu ihrer herstellung
ATE344276T1 (de) Polyamidnukleinsäure-derivate, mittel und verfahren zur ihrer herstellung
DE60238703D1 (de) Photokatalysator und verfahren zu seiner herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1330249

Country of ref document: EP